AlphaCentric Advisors’s Design Therapeutics DSGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$283K Buy
22,505
+968
+4% +$13.4K 0.25% 119
2026
Q2
$312K Buy
21,537
+306
+1% +$3.82K 0.26% 130
2026
Q1
$226K Buy
21,231
+969
+5% +$9.8K 0.23% 134
2025
Q4
$190K Buy
+20,262
New +$159K 0.19% 148

Other funds holding DSGN

AlphaCentric Advisors's DSGN Position: Q3 2026 in Review

AlphaCentric Advisors increased its Design Therapeutics (DSGN) stake by 4.5% in Q3 2026, buying an estimated $13.4K and bringing the position to 22,505 shares worth $283K. The position accounts for 0.25% of the portfolio, ranked #119.

AlphaCentric Advisors first reported a position in DSGN in Q4 2025 and has held it in 4 quarters since. The position peaked at $312K in Q2 2026. 94 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

  • AlphaCentric Advisors held 22,505 shares of Design Therapeutics worth $283K as of Q3 2026.
  • AlphaCentric Advisors bought 968 Design Therapeutics shares in Q3 2026, an estimated $13.4K.
  • Design Therapeutics made up 0.25% of AlphaCentric Advisors's portfolio in Q3 2026, its #119 holding.
  • AlphaCentric Advisors first reported a position in Design Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • AlphaCentric Advisors's Design Therapeutics position peaked at $312K in Q2 2026.
  • 94 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.